2022
Study of Biological Activities and ADMET-Related Properties of Novel Chlorinated N-arylcinnamamides
STRHARSKY, Tomas, Dominika PINDJAKOVA, Jiří KOS, Lucia VRABLOVA, Hana MICHNOVA et. al.Základní údaje
Originální název
Study of Biological Activities and ADMET-Related Properties of Novel Chlorinated N-arylcinnamamides
Autoři
STRHARSKY, Tomas (203 Česká republika), Dominika PINDJAKOVA, Jiří KOS (203 Česká republika, domácí), Lucia VRABLOVA, Hana MICHNOVA (203 Česká republika), Jan HOSEK (203 Česká republika), Nicol STRAKOVA (203 Česká republika), Veronika LELAKOVA (203 Česká republika), Lenka LEVA (203 Česká republika), Lenka KAVANOVA (203 Česká republika), Michal ORAVEC (203 Česká republika), Alois CIZEK (203 Česká republika) a Josef JAMPILEK (203 Česká republika)
Vydání
International Journal of Molecular Sciences, Basel, MDPI, 2022, 1422-0067
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
10608 Biochemistry and molecular biology
Stát vydavatele
Švýcarsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 5.600
Kód RIV
RIV/00216224:14110/22:00125675
Organizační jednotka
Lékařská fakulta
UT WoS
000775429300001
Klíčová slova anglicky
cinnamamides; antimicrobial activity; cytotoxicity; lipophilicity; structure-activity relationships
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 19. 4. 2022 09:25, Mgr. Tereza Miškechová
Anotace
V originále
A series of eighteen 4-chlorocinnamanilides and eighteen 3,4-dichlorocinnamanilides were designed, prepared and characterized. All compounds were evaluated for their activity against gram-positive bacteria and against two mycobacterial strains. Viability on both cancer and primary mammalian cell lines was also assessed. The lipophilicity of the compounds was experimentally determined and correlated together with other physicochemical properties of the prepared derivatives with biological activity. 3,4-Dichlorocinnamanilides showed a broader spectrum of action and higher antibacterial efficacy than 4-chlorocinnamanilides; however, all compounds were more effective or comparable to clinically used drugs (ampicillin, isoniazid, rifampicin). Of the thirty-six compounds, six derivatives showed submicromolar activity against Staphylococcus aureus and clinical isolates of methicillin-resistant S. aureus (MRSA). (2E)-N-[3,5-bis(trifluoromethyl)phenyl]- 3-(4-chlorophenyl)prop-2-enamide was the most potent in series 1. (2E)-N-[3,5-bis(Trifluoromethyl)phenyl]-3-(3,4-dichlorophenyl)prop-2-enamide, (2E)-3-(3,4-dichlorophenyl)-N-[3-(trifluoromethyl)phenyl]prop-2-enamide, (2E)-3-(3,4-dichloro- phenyl)-N-[4-(trifluoromethyl)phenyl]prop-2-enamide and (2E)-3-(3,4-dichlorophenyl)- N-[4-(trifluoromethoxy)phenyl]prop-2-enamide were the most active in series 2 and in addition to activity against S. aureus and MRSA were highly active against Enterococcus faecalis and vancomycin-resistant E. faecalis isolates and against fast-growing Mycobacterium smegmatis and against slow-growing M. marinum, M. tuberculosis non-hazardous test models. In addition, the last three compounds of the above-mentioned showed insignificant cytotoxicity to primary porcine monocyte-derived macrophages.
Návaznosti
90123, velká výzkumná infrastruktura |
|